Drug Type in vivo CAR-T therapy |
Synonyms SA 204, SA204 |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dermatomyositis | Preclinical | China | 01 Jul 2026 | |
| Multiple Sclerosis | Preclinical | China | 01 Jul 2026 | |
| Systemic Lupus Erythematosus | Preclinical | China | 01 Jul 2026 | |
| Colorectal Cancer | Discovery | China | 01 Nov 2024 | |
| Esophageal Carcinoma | Discovery | China | 01 Nov 2024 | |
| Stomach Cancer | Discovery | China | 01 Nov 2024 |





